Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Androcur Effects on Quality of Life

This study has been completed.
Sponsor:
Information provided by:
Bayer
ClinicalTrials.gov Identifier:
NCT00908674
First received: March 24, 2009
Last updated: April 12, 2010
Last verified: April 2010
  Purpose

Androcur is an antiandrogenic drug, which blocks the action of male sex hormones. Androcur is used for treatment of advanced prostate cancer. This study investigates the effect of Androcur on quality of life of prostate cancer patients who are taking the drug for 12 months


Condition Intervention
Prostate Cancer
Drug: Cyproterone acetate (Androcur)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Measure of Androcur Effects on Quality of Life at Prostate Cancer Patients

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Quality of life change measured by SF-35 questionnaire [ Time Frame: Baseline, after 3, 6 and 12 month ] [ Designated as safety issue: No ]

Enrollment: 245
Study Start Date: June 2008
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: Cyproterone acetate (Androcur)

The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).

Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.

Administration period: 12 months.


  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with advanced prostate cancer

Criteria

Inclusion Criteria:

  • Histologically confirmed adenocarcinoma of the prostate
  • Inoperable prostate tumor or progradiated after surgery/ irradiation therapy
  • Locally advanced tumor or distant metastases is present

Exclusion Criteria:

  • Patient not fulfil the recruitment criteria
  • Liver disease; Dubin-Johnson syndrome; Rotor syndrome; previous or existing liver tumours (in carcinoma of the prostate only if these are not due to metastases); wasting diseases (with the exception of carcinoma of the prostate); depression; previous or existing thromboembolic processes; diabetes with vascular changes; sickle-cell anaemia.
  • As regards patients with prostatic carcinoma who have a history of thromboembolic processes and/or an existing sickle-cell anaemia, or diabetes with vascular changes, the risk:benefit ratio must be considered carefully in each individual case before the use of Androcur
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00908674

Locations
Hungary
Many Locations, Hungary
Sponsors and Collaborators
Bayer
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
No publications provided

Responsible Party: Medical Director, Bayer Hungária Kft.
ClinicalTrials.gov Identifier: NCT00908674     History of Changes
Other Study ID Numbers: 14166, AC0710HU
Study First Received: March 24, 2009
Last Updated: April 12, 2010
Health Authority: Hungary: Council of Health Sciences Egeszsegügyi Tudomanyos Tanacs

Additional relevant MeSH terms:
Prostatic Neoplasms
Genital Diseases, Male
Genital Neoplasms, Male
Neoplasms
Neoplasms by Site
Prostatic Diseases
Urogenital Neoplasms
Cyproterone
Cyproterone Acetate
Androgen Antagonists
Antineoplastic Agents
Contraceptive Agents
Contraceptive Agents, Male
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Pharmacologic Actions
Physiological Effects of Drugs
Reproductive Control Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2014